A L Serban1,2, G Del Sindaco1,3, E Sala1, G Carosi1,3, R Indirli1,3, G Rodari1,3, C Giavoli1,3, M Locatelli4,5, G Carrabba4, G Bertani4, G Marfia4, G Mantovani6,7, M Arosio1,3, E Ferrante1. 1. Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Endocrinology Unit, Via Francesco Sforza, 35, Milan, 20143, Italy. 2. Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. 3. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. 4. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Neurosurgery Division, Milan, Italy. 5. Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy. 6. Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Endocrinology Unit, Via Francesco Sforza, 35, Milan, 20143, Italy. giovanna.mantovani@unimi.it. 7. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy. giovanna.mantovani@unimi.it.
Abstract
BACKGROUND: First-line therapy of Cushing disease (CD) is transsphenoidal surgery (TSS) aimed to obtain a complete removal of the pituitary adenoma and remission of disease. PURPOSE: To analyse the surgical outcome of patients with CD who underwent TSS in our Centre. METHODS: Retrospective analysis on patients with CD who underwent TSS between 1990 and 2016. RESULTS: We analysed 102 TSS that included: 84 first TSS and 18 second and third TSS. The overall remission rate after surgery was 76.5%, with a significant higher percentage of remitted patients after the first TSS compared to the subsequent TSS (82% vs 50%, p = 0.014). The remission after the first TSS was significantly higher when performed by a dedicated surgical team (DST) (89.8% vs 71% p = 0.04) and when the immunohistochemical examination confirmed the adrenocorticotropic adenoma (87% vs 55%, p = 0.04). Neuroradiological findings influenced the surgical outcome in a non-significant manner. Post-TSS complications were reported in 32 patients, with no significant variation when TSS was performed by DST. In case of reintervention, remission of disease was obtained in 72.7% of microadenoma, while no remitted patients were observed in case of macroadenomas. The DST did not significantly improve the outcome. CONCLUSION: Cushing disease is characterized by a broad spectrum of neuroradiological presentation. Despite the availability of a DST make the TSS a safe and effective first-line treatment among all these patients, a precise pre-treatment evaluation is needed in order to define the aim of neurosurgery and to schedule the management of recurrent disease.
BACKGROUND: First-line therapy of Cushing disease (CD) is transsphenoidal surgery (TSS) aimed to obtain a complete removal of the pituitary adenoma and remission of disease. PURPOSE: To analyse the surgical outcome of patients with CD who underwent TSS in our Centre. METHODS: Retrospective analysis on patients with CD who underwent TSS between 1990 and 2016. RESULTS: We analysed 102 TSS that included: 84 first TSS and 18 second and third TSS. The overall remission rate after surgery was 76.5%, with a significant higher percentage of remitted patients after the first TSS compared to the subsequent TSS (82% vs 50%, p = 0.014). The remission after the first TSS was significantly higher when performed by a dedicated surgical team (DST) (89.8% vs 71% p = 0.04) and when the immunohistochemical examination confirmed the adrenocorticotropic adenoma (87% vs 55%, p = 0.04). Neuroradiological findings influenced the surgical outcome in a non-significant manner. Post-TSS complications were reported in 32 patients, with no significant variation when TSS was performed by DST. In case of reintervention, remission of disease was obtained in 72.7% of microadenoma, while no remitted patients were observed in case of macroadenomas. The DST did not significantly improve the outcome. CONCLUSION:Cushing disease is characterized by a broad spectrum of neuroradiological presentation. Despite the availability of a DST make the TSS a safe and effective first-line treatment among all these patients, a precise pre-treatment evaluation is needed in order to define the aim of neurosurgery and to schedule the management of recurrent disease.
Entities:
Keywords:
Cushing disease; Hypercortisolism; Remission; Transsphenoidal surgery
Authors: G Arnaldi; A Angeli; A B Atkinson; X Bertagna; F Cavagnini; G P Chrousos; G A Fava; J W Findling; R C Gaillard; A B Grossman; B Kola; A Lacroix; T Mancini; F Mantero; J Newell-Price; L K Nieman; N Sonino; M L Vance; A Giustina; M Boscaro Journal: J Clin Endocrinol Metab Date: 2003-12 Impact factor: 5.958
Authors: V Levi; G A Bertani; C Guastella; L Pignataro; M L P F Zavanone; P M Rampini; M A R Caroli; E Sala; E Malchiodi; G Mantovani; G G Carrabba; M Locatelli Journal: Clin Otolaryngol Date: 2016-03-04 Impact factor: 2.597
Authors: Chirag G Patil; Anand Veeravagu; Daniel M Prevedello; Laurence Katznelson; Mary L Vance; Edward R Laws Journal: Neurosurgery Date: 2008-08 Impact factor: 4.654
Authors: William F Chandler; Ariel L Barkan; Todd Hollon; Alla Sakharova; Jayson Sack; Barunashish Brahma; David E Schteingart Journal: Neurosurgery Date: 2016-02 Impact factor: 4.654
Authors: Leonie H A Broersen; Nienke R Biermasz; Wouter R van Furth; Friso de Vries; Marco J T Verstegen; Olaf M Dekkers; Alberto M Pereira Journal: Pituitary Date: 2018-10 Impact factor: 4.107
Authors: Carlos Perez-Vega; Andres Ramos-Fresnedo; Shashwat Tripathi; Ricardo A Domingo; Krishnan Ravindran; Joao P Almeida; Jennifer Peterson; Daniel M Trifiletti; Kaisorn L Chaichana; Alfredo Quinones-Hinojosa; Susan L Samson Journal: Pituitary Date: 2022-05-04 Impact factor: 4.107